Cardiac Bio Marker Diagnostic Test Market

Cardiac Biomarker Diagnostic Test Kits Market: BNP Test Kits to Remain Largest Product Type: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

  • 2018-10-11
  • REP-GB-452
  • 239 pages
  • PDF PPT EXCEL
Cardiac Bio Marker Diagnostic Test Market

An Incisive, In-depth Analysis on the Cardiac Bio Marker Diagnostic Test Market

This study offers a comprehensive, 360 degree analysis on the Cardiac Bio Marker Diagnostic Test market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Cardiac Bio Marker Diagnostic Test market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Market Value and Forecast

The global cardiac biomarker diagnostic test kits market is expected to be worth US$ 2,540.8 Mn in 2028, and is projected to increase at a CAGR of 5.1% through 2028. North America is expected to be a dominant market, which accounted for US$ 522.5 Mn in 2017, and is expected to grow at a CAGR of 4.3%.

Key Insights

  • Troponin biomarkers among all the cardiac biomarker diagnostic test kits are more sensitive, hence they are mostly preferred by the medical professionals for the diagnosis of cardiovascular diseases.

  • Chest pain is a common emergency department (ED) presentation accounting for 8–10 million visits per year in the U.S., among which 20% of patients are diagnosed with the help of cardiac biomarker diagnostic test kits for cardiovascular diseases.

  • Adoption of BNP test kits is growing in the global cardiac biomarker diagnostic test kits market due to rising incidence of heart failure, where BNP cardiac biomarker diagnostic test test kits are mostly preferred for the detection of heart failure.

  • Assay-based cardiac biomarker diagnostic test is most often performed at diagnostic laboratories, hence the end-use segment it estimated to gain maximum value share in the cardiac biomarker diagnostic test kits market.

  • India is expected to grow at a significant rate in the APECJ cardiac biomarker diagnostic test kits market among all the countries, as approximately 3.1% adult population in India is suffering from angina pectoris due to obesity.

  • Cardiovascular diseases (CVDs) constitute the second leading cause of deaths in France, accounting for 27% of the 535,000 deaths in 2011. Thus, increasing prevalence of CVDs is expected to contribute to the growth of the cardiac biomarker diagnostic test kits market in France.

  • Approximately, 6.5% adult population is suffering from angina pectoris due to obesity in China, which consequently is expected to lead to robust growth of the cardiac biomarker diagnostic test kits market in China.

  • MEA is expected to witness sluggish growth owing to less adoption of cardiac biomarker diagnostic test kits for the diagnosis of cardiovascular disease and lack of awareness regarding their benefits among the general population.

Factors and Trends Impacting the Growth of the Market

The per capita healthcare expenditure is currently following an uptrend across both developed and developing economies, which is expected to increase the need for quality patient care treatment options and ultimately increase the demand for cardiac biomarker diagnostic test kits. The rising demand for lab diagnostics for detection of cardiovascular diseases throughout the globe has led the manufacturers to launch their cardiac biomarker diagnostic test kits across various geographies. Inorganic strategies are contributing to the revenue growth of the participants operating in the cardiac biomarker diagnostic test market—a well noted phenomenon in developed markets, e.g., the acquisition of Alere Inc. by Abbott Laboratories.

This inorganic growth strategy followed by the key players in the cardiac biomarker diagnostic test kits market has led to a stiff competition among the existing players. Heart attack has become a global issue, affecting more than 26 million people throughout the globe. The prevalence of heart failure is increasing rapidly due to rising geriatric population throughout the globe, which will ultimately increase the demand for cardiac biomarker diagnostic test kits. On the other hand, less availability of cardiac biomarker diagnostic test kits to diagnose strokes is expected to deter the growth of the cardiac biomarker diagnostic test market over the forecast period.

Key Players

Examples of some of the key players operating in the global cardiac biomarker diagnostic test kits market are Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens AG, bioMérieux SA, and Randox Laboratories Ltd., among others. The leading manufacturers of cardiac biomarker diagnostic test kits are focusing on collaborating with universities to manufacture innovative products for the diagnosis of cardiovascular diseases. Some of the companies are focusing on to collaborate directly with hospitals to promote their cardiac biomarker diagnostic test kits. On the other hand, few players of cardiac biomarker diagnostic test kits are emphasizing on collaboration with distributors to expand their regional presence.

This Future Market Insights (FMI) report examines the ‘Global Cardiac Biomarker Diagnostic Test Kits Market’ for the period 2018–2028. The primary objective of the report is to offer updates and information related to the opportunities in the global cardiac biomarker diagnostic test kits market.

The Cardiac Biomarker Diagnostic Test Kits Market is Segmented Based on:

  • Product Type
  • Indication
  • End Users
  • Region

This report covers the global cardiac biomarker diagnostic test kits market performance in terms of revenue contribution from various segments. The report begins with an overview of the cardiac biomarker diagnostic test kits and their definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the cardiac biomarker diagnostic test kits market along with detailing its opportunity analysis. This section also highlights the drivers and restraints of the cardiac biomarker diagnostic test kits market along with the key trends.

The global cardiac biomarker diagnostic test kits market is segmented based on product type, indication, end users, and region. On the basis of product type, the cardiac biomarker diagnostic test kits market has been segmented as Brain Natriuretic Peptide (BNPs) Test Kits, Creatine Kinase MB (CK-MB) Test Kits, Troponin (I&T) Tests Kits, Myoglobin Test Kits and other test kits. On the basis of indication, the cardiac biomarker diagnostic test kits market is segmented as Angina Pectoris, Acute Myocardial Infarction, Congestive Heart Failure, and Others. On the basis of end users, the cardiac biomarker diagnostic test kits market is segmented as hospitals, diagnostic laboratories, outpatient clinics, academic and research institutes.

A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The key points responsible for the growth of the market in respective region is highlighted in the summary slide. The forecast of the cardiac biomarker diagnostic test kits market by country, product type, indication, and end user is represented in a tabular form for each region. This section also helps to understand the opportunity of the cardiac biomarker diagnostic test kits market in major countries by each segment.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. This section also provide wise structure analysis to understand the tier structure of cardiac biomarker diagnostic test kits market. Along with the tier structure, the section also assesses the market share analysis of the top companies to cross-validate the cardiac biomarker diagnostic test kits market in terms of value. This analysis is done on a granular level by analysing the revenue generated by each of the manufacturer in the cardiac biomarker diagnostic test kits market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of the key providers specific to the market segments. Detailed profiles of players in the cardiac biomarker diagnostic test kits market are also provided in the report, which highlight company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the cardiac biomarker diagnostic test kits market outlook for 2018–2028 and sets the forecast within the context of the cardiac biomarker diagnostic test kits market by region. The key regions assessed in the report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China and Japan, China, Japan and Middle East & Africa. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. This section helps to analyse the maturity level of all the regions in the global cardiac biomarker diagnostic test kits market.

The above sections – by product type, indication and end user – evaluate the historic market analysis for the period of 2013–2017 and growth prospects of the cardiac biomarker diagnostic test kits market for the period 2018–2028. Along with historic analysis, the market value forecast and Y-o-Y analysis by product type and end user for the cardiac biomarker diagnostic test kits market is also provided in this section. We have considered 2017 as the base year and provided data for the forecast period.

The final section of report represents the global scenario for the cardiac biomarker diagnostic test kits market along with Y-o-Y growth and market forecast till 2028. This section also evaluates the global market opportunity over the forecast period and also the absolute dollar opportunity for each year. This section will help to understand the overall market growth of the cardiac biomarker diagnostic test kits market and the opportunity analysis for each year over the forecast period. This section also provides the volume analysis for the global cardiac biomarker diagnostic test kits market to analyse the global sale of cardiac biomarker diagnostic test kits.

Research Methodology

Initially top-down analysis is used to calculate the size of the global cardiac biomarker diagnostic test kits market. Firstly, the prevalence of Angina Pectoris, Acute Myocardial Infarction, and Congestive Heart Failure is tracked in top 20 countries by secondary research. This has provided us the total number of prevalent cases using cardiac biomarker diagnostic test kits. Then, the adoption of cardiac biomarker diagnostic test kits for the diagnosis of cardiovascular disease is analysed from the primary respondents. This has provided us the actual number of patients adopting cardiac biomarker test kits for the diagnosis of cardiovascular diseases. Total number of tests performed per patient is also analysed with the help of primary respondent. This has provided us the total volume of cardiac biomarker diagnostics test kits. Prices of various cardiac biomarker diagnostic test kits available in the market are analysed to calculate the average selling price of each type of cardiac biomarker diagnostic test kit. The volume of cardiac biomarker diagnostic test kits is then multiplied with the average selling price to obtain the market value of cardiac biomarker diagnostic test kits in 2017 for top countries.

Bottom-up approach is used to validate the total market size obtained. The forecast presented in the report provides total revenue of the cardiac biomarker diagnostic test kits market over 2018–2028. While forecasting the market size, we have considered the impact of several factors such product approvals for cardiac biomarker diagnostic test kits, R&D investment by major players, pipeline analysis, penetration of products in all end user facilities channel, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market

Cardiac Bio Marker Diagnostic Test Market Reports - Table of Contents

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology